Welcome to our dedicated page for Elutia news (Ticker: $ELUT), a resource for investors and traders seeking the latest updates and insights on Elutia stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Elutia's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Elutia's position in the market.
Elutia Inc. (Nasdaq: ELUT) announced its first quarter 2024 results, highlighting a 55% increase in sales for SimpliDerm® and positive progress with FDA interactions for CanGaroo®RM. With a focus on disruptive technology in the pacemaker and defibrillator protection market, Elutia aims to set new standards for patient outcomes. The financial results showcased overall revenue growth, with net sales reaching $6.7 million and a gross margin of 42% on a GAAP basis. Despite a decline in cardiovascular product sales, Elutia remains optimistic about the pending FDA decision for CanGarooRM and the commercial launch expected in the second half of 2024.
Elutia Inc. (Nasdaq: ELUT) will report its first quarter 2024 financial results on May 9, 2024. The company specializes in drug-eluting biomatrix products. A conference call and webcast will be held on the same day.